Further studies on imidazo[4,5-b] pyridine AT1 angiotensin II receptor antagonists.: Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds

被引:80
作者
Cappelli, Andrea
Mohr, Gal. la Pericot
Giuliani, Germano
Galeazzi, Simone
Anzini, Maurizio
Mennuni, Laura
Ferrari, Flora
Makovec, Francesco
Kleinrath, Eva M.
Langer, Thierry
Valoti, Massimo
Giorgi, Gianluca
Vomero, Salvatore
机构
[1] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy
[2] Univ Siena, European Res Ctr Drug Discovery & Dev, I-53100 Siena, Italy
[3] Rotta Res Lab SpA, I-20052 Monza, Italy
[4] Univ Innsbruck, Inst Pharm, Dept Pharmaceut Chem, A-6020 Innsbruck, Austria
[5] Univ Siena, Dipartimento Sci Biomed, I-53100 Siena, Italy
[6] Univ Siena, Dipartimento Chim, I-53100 Siena, Italy
关键词
D O I
10.1021/jm0603163
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 4-phenylquinoline fragment of novel AT(1) receptor antagonists 4 based on imidazo[ 4,5-b] pyridine moiety was replaced by 4-phenylisoquinolinone (compounds 5) or 1-phenylindene (compounds 6) scaffolds to investigate the structure-activity relationships. Binding studies showed that most of the synthesized compounds display high affinity for the AT(1) receptor. Because of the in vitro high potency of carboxylic acids 5b, f, they were evaluated in permeability (in Caco-2 cells) and in pharmacokinetic studies in comparison with quinoline derivatives 4b, i, j, k. The studies showed that these compounds are characterized by rapid excretion, low membrane permeability, and low oral bioavailability. The structure optimization of the indene derivatives led to compounds 6e, f possessing interesting AT(1) receptor affinities. Optimization produced polymerizing AT(1) receptor ligand 6c, which forms a thermoreversible polymer (poly-6c) and is released from the latter by a temperature-dependent kinetics. The results suggest the possibility of developing novel polymeric prodrugs based on a new release mechanism. Finally, a set of 34 AT(1) receptor antagonists was used as a new test for the evaluation of the predictive capability of the previously published qualitative and quantitative pharmacophore models.
引用
收藏
页码:6451 / 6464
页数:14
相关论文
共 38 条
[31]   EFFECTS OF PEPTIDASE INHIBITION ON ANGIOTENSIN RECEPTOR AGONIST AND ANTAGONIST POTENCY IN RABBIT ISOLATED THORACIC AORTA [J].
ROBERTSON, MJ ;
CUNOOSAMY, MP ;
CLARK, KL .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 106 (01) :166-172
[32]   Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites [J].
Schmidt, B ;
Schieffer, B .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (12) :2261-2270
[33]  
Senanayake CH, 1996, HETEROCYCLES, V42, P821
[34]  
Sheldrick G.M., 1997, SHELXS 97 REL 97 2 P
[35]  
SHELDRICK GM, 1997, SHELXL 97 REL 97 2 P
[36]   Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers [J].
Soldner, A ;
Benet, LZ ;
Mutschler, E ;
Christians, U .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (06) :1235-1243
[37]  
SUZUKI K, 1994, Patent No. 0692939
[38]   Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy [J].
Wexler, RR ;
Greenlee, WJ ;
Irvin, JD ;
Goldberg, MR ;
Prendergast, K ;
Smith, RD ;
Timmermans, PBMWM .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :625-656